Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study to Compare Four Dose Regimens of GLPG0634 Versus Placebo, in Combination With Methotrexate, Administered for 4 Weeks in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Alone

NCT01668641 is registered in ClinicalTrials.gov with Lakefront Biotherapeutics NV as lead sponsor.

NCT NCT01668641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01668641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study to Compare Four Dose Regimens of GLPG0634 Versus Placebo, in Combination With Methotrexate, Administered for 4 Weeks in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Alone
Lead sponsor
Lakefront Biotherapeutics NV
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2012
Completion date
October 31, 2012
Enrollment
91 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis